Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review (Q36045044)

11 August 2017

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review (English)

1 reference

11 August 2017

0 references

1 reference

Emmert Roberts

2

0 references

author name string

Lucy E Farrimond

series ordinal

1

1 reference

PMC publication ID

3378937

11 August 2017

Rupert McShane

series ordinal

3

1 reference

11 August 2017

11 June 2012

1 reference

11 August 2017

1 reference

11 August 2017

2

1 reference

11 August 2017

3

1 reference

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3378937

Combination therapy for Alzheimer's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3378937

Lack of evidence for the efficacy of memantine in mild Alzheimer disease.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3378937

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3378937

Memantine induces reversible neurologic impairment in patients with MS.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3378937

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3378937

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3378937

Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3378937

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3378937

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3378937

10.1136/BMJOPEN-2012-000917

23 September 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PMC publication ID

3378937

11 August 2017

PubMed publication ID

22689908

1 reference

PMC publication ID

3378937